ArticleCancer medicine2025
Nationwide Genomic Data Analysis of Japanese Prostate Cancer Patients From C-CAT Database.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Circulating Tumor DNA Genomic Profiling inJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Observational
- Nationwide Genomic Data Analysis of Japanese Prostate Cancer Patients From C-CAT Database.Cancer medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeProstate cancer is a leading malignancy among men, and genomic alterations are known to impact disease progression and treatment response. However, racial and ethnic differences may influence genomic profiles, necessitating population-specific analyses. This study aimed to characterize the genomic landscape and its clinical significance in Japanese patients with treatment-resistant, unresectable prostate cancer using data from the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database.
methodsWe analyzed data from patients with advanced or metastatic prostate cancer who had progressed after standard therapies and underwent comprehensive genomic profiling between 2019 and 2022. We assessed the frequency of genomic alterations, tumor mutation burden (TMB), and microsatellite instability (MSI) status. Associations between genomic features and clinical outcomes were also examined.
resultsA total of 2634 patients were included. Family history was reported in 12.5% for prostate cancer, 1.5% for breast cancer, 5.2% for pancreatic cancer, and 1.1% for ovarian cancer. AR gene alterations were observed in 18% of patients. TP53 and BRCA2 mutations were identified in 34% and 12% of cases, respectively. Mutations in TP53, as well as alterations in genes related to the cell cycle, epigenetic regulation, MYC signaling, and the PI3K pathway, were associated with poorer overall survival.
conclusionsThis study provides a comprehensive overview of genomic alterations in advanced prostate cancer among Japanese patients and identifies key mutations linked to prognosis. These findings highlight the value of personalized prognostic assessment based on genomic profiling to guide clinical decision-making in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.